<DOC>
	<DOCNO>NCT00772876</DOCNO>
	<brief_summary>This phase I study novel compound P1446A-05 . Aim study identify recommend phase II dose drug determine nature adverse effect associate drug . P1446A-05 capsule give continuously ( 28 day 28 day cycle ) patient suffer advanced malignancy effective treatment available . The dose study agent low i.e . 75 mg per day initial patient . If dose find safe , high dose administer next set ( three six ) patient . This continue till safe best dose identify . Treatment give 4 cycle continue found effective . Dose schedule may modify introduce treatment holiday , frequent adverse effect see continuous administration .</brief_summary>
	<brief_title>A Multicenter Phase I Clinical Study New Compound P1446A-05 Patients With Advanced Refractory Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Cyclin-Dependent Kinase Inhibitor Proteins</mesh_term>
	<criteria>Histologically and/ cytologically confirm solid malignant tumor Malignant Lymphoma ( exclude CNS Lymphoma multiple myeloma ) refractory currently available treatment standard treatment exist Measurable disease Must complete prior chemotherapy , radiotherapy , biologic/targeted anticancer therapy surgery least 4 week ( least 6 week nitrosureas mitomycin C ; 3 month monoclonal antibody , radioactive monoclonal antibody radio toxin immunoconjugates ) study entry subject must recover ( ≤grade 1 ) toxic effect prior therapy . Must 40 % bone marrow radiate must either measurable disease outside field progression post radiation therapy . Age ≥ 18 year ECOG performance status ≤ 2 Life expectancy least 12 week Normal organ marrow function define : Hemoglobin &gt; /= 90 g/L Leukocytes &gt; /=3 x 109/L Absolute Neutrophil Count ( ANC ) &gt; /=1.5 x 109/L Platelets &gt; /=100 x 109/L Total bilirubin &lt; /= 1.5 X institutional Upper Limit Normal ( ULN ) AST ( SGOT ) &lt; /=2.5 X institutional ULN ALT ( SGPT ) &lt; /=2.5 X institutional ULN Creatinine &lt; /=1.5 X institutional ULN Ability understand willingness sign write informed consent document . autologous allogeneic bone marrow transplant within 6 month day 1 study drug administration Known brain metastasis time screen Any investigational drug within 1 month prior day 1 study drug administration recover ( ≤grade 1 ) adverse effect investigational agent receive prior period . History allergic reaction attribute compound similar chemical structure P1446A05 . On immunosuppressive therapy . History unstable angina myocardial infarction stroke within 6 month prior Day 1 study drug administration . Uncontrolled intercurrent illness include , limited active infection , symptomatic congestive heart failure , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Known suffer infection HIV , Tuberculosis , Hepatitis C Hepatitis B . Pregnant lactate woman Women childbearing potential [ define sexually mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month ( i.e . menses time precede 24 consecutive month ) ] men , agree use adequate contraception ( two method contraception , include least one barrier method , i.e . : hormonal barrier method birth control abstinence ) prior study entry ( sign inform consent document ) , duration study participation least 4 week withdrawal study drug , unless surgically sterilise . Any condition , include laboratory abnormality , opinion investigator place subject unacceptable risk deems subject suitable participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>P1446A-05</keyword>
	<keyword>Advanced refractory malignancy</keyword>
	<keyword>Phase I</keyword>
</DOC>